Extraordinary Promise for Tβ4 Peptide: From Laboratory to Clinical Use

Review of preclinical and early clinical Thymosin Beta-4 (Tβ4) research across multiple model systems. Data drawn from murine cardiac infarction models, skeletal muscle injury models, corneal wound healing studies, and neurological injury models. ILK pathway activation was characterised via kinase inhibition and knockout studies.

Tβ4 demonstrated significant repair-promoting effects across four major tissue systems: (1) Cardiac: reduced infarct size, improved ejection fraction, and cardiomyocyte survival in MI models; (2) Musculoskeletal: accelerated skeletal muscle regeneration via satellite cell activation, improved tendon repair; (3) Corneal: significantly faster epithelial closure in corneal wound models, now in Phase II clinical trials; (4) Neurological: neurite outgrowth promotion, reduced neuroinflammation markers. ILK was identified as the central signalling node: Tβ4 activates ILK, which phosphorylates Akt and ERK1/2, promoting survival and migration signals in multiple cell types. The authors describe Tβ4 as having "extraordinary promise" for translation to clinical applications.

Most data remain preclinical; human clinical evidence is limited to corneal healing (Phase II) and early cardiac studies. Tβ4''s multi-system activity, while promising, also complicates mechanistic interpretation and safety profiling. Large-scale randomised clinical trials are not yet available.

This review provides the comprehensive rationale for TB-500 (Tβ4 synthetic analog) as a multi-system repair peptide and identifies ILK as the primary signalling mechanism. It is the key reference for researchers considering TB-500 in musculoskeletal, cardiac, or wound healing research contexts.